Proton pump inhibitors: Impact on glucose metabolism

Endocrine

Volumn 43, Issue 1, 2013, Pages 22-32

  Boj Carceller, Diana ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Diabetes; Incretins; Proton pump inhibitors; Treatment

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CLOPIDOGREL; CYTOCHROME P450 2C19; EPIDERMAL GROWTH FACTOR; ESOMEPRAZOLE; GASTRIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LANSOPRAZOLE; METFORMIN; OCTREOTIDE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; SITAGLIPTIN; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; THIAZOLIDINE DERIVATIVE;

ACROMEGALY; ANTIDIABETIC ACTIVITY; ATROPHIC GASTRITIS; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; FRACTURE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HORMONE INHIBITION; HUMAN; HYPERGASTRINEMIA; HYPERINSULINEMIA; HYPOMAGNESEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOPOROSIS; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STOMACH EMPTYING;

EID: 84872339752     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9755-3     Document Type: Review

References (88)

1. International Diabetes Federation. Diabetes and impaired glucose tolerance: global burden: prevalence and projections, 2010 and 2030. International Diabetes Federation Website. http://www.idf.org/diabetesatlas/5e/ the-global-burden (2011). Accessed 9 Apr 2012
2. J.E. Shaw, R.A. Sicree, P.Z. Zimmet, Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87, 4-14 (2010)
3. R.A. Defronzo, Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773-795 (2009)
4. Menéndez Torre E., Lafita Tejedor F.J., Artola Menéndez S., Millán Núñez-Cortés J., Alonso García Á., Puig Domingo M. et al. Working Group for Consensus and Clinical Guidelines of the Spanish Diabetes Society. Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. Endocrinol. Nutr. 58, 112-120 (2011)
5. G. Dockray, R. Dimaline, A. Varro, Gastrin: old hormone, new functions. Pflugers Arch. 449, 344-355 (2005)
6. I. Rooman, J. Lardon, L. Bouwens, Gastrin stimulates β-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 51, 686-690 (2002)
7. W.L. Suarez-Pinzon, Y. Yan, R. Power, S.J. Brand, A. Rabinovitch, Combination therapy with epidermal growth factor and gastrin increases β-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 54, 2596-2601 (2005)
8. W.L. Suarez-Pinzon, J.R. Lakey, S.J. Brand, A. Rabinovitch, Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet β-cells from pancreatic duct cells and an increase in functional β-cell mass. J. Clin. Endocrinol. Metab. 90, 3401-3409 (2005)
9. E. Sheen, G. Triadafilopoulos, Adverse effects of long-term proton pump inhibitor therapy. Dig. Dis. Sci. 56, 931-950 (2011)
10. M.S. McDonagh, S. Carson, S. Thakurta, Drug Class Review: Proton Pump Inhibitors. Final Report Update 5 (Oregon Health and Science University, Portland, 2009)
11. I.N. Mefford, E.U. Wade, Proton pump inhibitors as a treatment method for type II diabetes. Med. Hypotheses 73, 29-32 (2009)
12. D. Boj-Carceller, P. Bocos-Terraz, M. Moreno-Vernis, A. Sanz-Paris, P. Trincado-Aznar, R. Albero-Gamboa, Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J. Diabetes 2, 217-220 (2011)
13. K.D. Hove, K. Færch, T.B. Bödvarsdóttir, A.E. Karlsen, J.S. Petersen, A. Vaag, Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients - a retrospective analysis. Diabetes Res. Clin. Pract. 90, e72-e74 (2010)
14. N. Parikh, C.W. Howden, The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol. Clin. N. Am. 39, 529-542 (2010)
15. M. Robinson, Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors - overview and clinical implications. Aliment. Pharmacol. Ther. 20, 1-10 (2004)
16. M.M. Wolfe, A.H. Soll, The physiology of gastric acid secretion. N. Engl. J. Med. 319, 1707-1715 (1988)
17. M.M. Wolfe, G. Sachs, Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 118, S9-S31 (2000)
18. J. Horn, Review article: relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabeprazole. Aliment. Pharmacol. Ther. 20, 11-19 (2004)
19. R.W. Harrison, K.W. Mahaffey, Clopidogrel and PPI interaction: clinically relevant or not? Curr. Cardiol. Rep. 14, 49-58 (2012)
20. A.S. Raghunath, C. O'Morain, R.C. McLoughlin, Review article: the long-term use of proton-pump inhibitors. Aliment. Pharmacol. Ther. 22, 55-63 (2005)
21. A.B. Thomson, M.D. Sauve, N. Kassam, H. Kamitakahara, Safety of the long-term use of proton pump inhibitors. World J. Gastroenterol. 16, 2323-2330 (2010)
22. J. Chen, Y.C. Yuan, G.I. Leontiadis, C.W. Howden, Recent safety concerns with proton pump inhibitors. J. Clin. Gastroenterol. 46, 93-114 (2012)
23. S.P. Marcuard, L. Albernaz, P.G. Khazanie, Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann. Intern. Med. 120, 211-215 (1994)
24. E.C. Klinkenberg-Knol, F. Nelis, J. Dent, P. Snel, B. Mitchell, P. Prichard et al., Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118, 661-669 (2000)
25. R.A. Gregory, H.J. Tracy, J.I. Harris, M.J. Runswick, S. Moore, G.W. Kenner et al., Minigastrin; corrected structure and synthesis. Hoppe Seylers Z. Physiol. Chem. 360, 73-80 (1979)
26. M.D. Burkitt, A. Varro, D.M. Pritchard, Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J. Gastroenterol. 15, 1-16 (2009)
27. S.J. Brand, B.N. Andersen, J.F. Rehfeld, Complete tyrosine-o-sulphation of gastrin in neonatal rat pancreas. Nature 6, 456-458 (1984)
28. D. Chen, C.M. Zhao, R. Håkanson, L.C. Samuelson, J.F. Rehfeld, L. Friis-Hansen, Altered control of gastric acid secretion in gastrin- cholecystokinin double mutant mice. Gastroenterology 126, 476-487 (2004)
29. C. Saillan-Barreau, M. Dufresne, P. Clerc, D. Sanchez, H. Corominola, C. Moriscot et al., Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas. Diabetes 48, 2015-2021 (1999)
30. I. Rooman, J. Lardon, D. Flamez, F. Schuit, L. Bouwens, Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas. Gastroenterology 121, 940-949 (2001)
31. J.F. Rehfeld, Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol. (Oxf). 201, 405-411 (2011)
32. J. Dupre, J.D. Curtis, R.H. Unger, R.W. Waddell, J.C. Beck, Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J. Clin. Invest. 48, 745-757 (1969)
33. A. Kaneto, Y. Tasaka, K. Kosaka, K. Nakao, Stimulation of insulin secretion by the C-terminal tetrapeptide amide of gastrin. Endocrinology 84, 1098-1106 (1969)
34. H. Ohgawara, Y. Mizuno, Y. Tasaka, K. Kosaka, Effect of the C-terminal tetrapeptide amide of gastrin on insulin secretion in man. J. Clin. Endocrinol. Metab. 29, 1261-1262 (1969)
35. J.F. Rehfeld, F. Stadil, The effect of gastrin on basal- and glucose-stimulated insulin secretion in man. J. Clin. Invest. 52, 1415-1426 (1973)
36. W.L. Suarez-Pinzon, R.F. Power, Y. Yan, C. Wasserfall, M. Atkinson, A. Rabinovitch, Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57, 3281-3288 (2008)
37. S.Y. Song, M. Gannon, M.K. Washington, C.R. Scoggins, I.M. Meszoely, J.R. Goldenring et al., Expansion of PDX-1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor α. Gastroenterology 117, 1416-1426 (1999)
38. K. Yamamoto, J. Miyagawa, M. Waguri, R. Sasada, K. Igarashi, M. Li et al., Recombinant human betacellulin promotes the neogenesis of β-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes 49, 2021-2027 (2000)
39. C. Cras-Meneur, L. Elghazi, P. Czernichow, R. Scharfmann, Epidermal growth factor increases undifferentiated pancreatic embryonic cells in vitro: a balance between proliferation and differentiation. Diabetes 50, 1571-1579 (2001)
40. M.L. Krakowski, M.R. Kritzik, E.M. Jones, T. Krachl, J. Lee, M. Arnush et al., Transgenic expression of epidermal growth factor and keratinocyte growth factor in β-cells results in substantial morphological changes. J. Endocrinol. 162, 167-175 (1999)
41. G. Xu, D.A. Stoffers, J.F. Habener, S. Bonner-Weir, Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48, 2270-2276 (1999)
42. R.N. Wang, G. Klöppel, L. Bouwens, Duct- to islet-cell differentiation and islet growth in the pancreas of duct-ligated adult rats. Diabetologia 38, 1405-1411 (1995)
43. R.N. Wang, J.F. Rehfeld, F.C. Nielsen, G. Klöppel, Expression of gastrin and transforming growth factor-alpha during duct to islet cell differentiation in the pancreas of duct-ligated adult rats. Diabetologia 40, 887-893 (1997)
44. I. Rooman, L. Bouwens, Islet neogenesis in the regeneration model of rat pancreatic duct ligation requires endogenous gastrin action via CCK2 receptors. Diabetologia 45(Suppl. 2), A26 (2002)
45. G. Xu, S. Sumi, M. Koike, K. Tanigawa, Y. Nio, K. Tamura, Role of endogenous hypergastrinemia in regenerating endocrine pancreas after partial pancreatectomy. Dig. Dis. Sci. 41, 2433-2439 (1996)
46. E.P. Sandgren, N.C. Luetteke, R.D. Palmiter, R.L. Brinster, D.C. Lee, Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61, 1121-1135 (1990)
47. T.C. Wang, S. Bonner-Weir, P.S. Oates, M. Chulak, B. Simon, G.T. Merlino et al., Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-induced ductular precursor cells. J. Clin. Invest. 92, 1349-1356 (1993)
48. S.J. Brand, S. Tagerud, P. Lambert, S.G. Magil, K. Tartarkiewicz, K. Doiron et al., Pharmacological treatment of chronic diabetes by stimulating pancreatic β-cell regeneration with systemic co-administration of EGF and gastrin. Pharmacol. Toxicol. 91, 414-420 (2002)
49. I. Rooman, L. Bouwens, Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycemia in C57BL6/J mice treated with alloxan. Diabetologia 47, 259-265 (2004)
50. P.L. Brubaker, D.J. Drucker, Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 145, 2653-2659 (2004)
51. A. Bulotta, L. Farilla, H. Hui, R. Perfetti, The role of GLP-1 in the regulation of islet cell mass. Cell Biochem. Biophys. 40, 65-78 (2004)
52. W.L. Suarez-Pinzon, J.R. Lakey, A. Rabinovitch, Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant. 17, 631-640 (2008)
53. W.L. Suarez-Pinzon, G.S. Cembrowski, A. Rabinovitch, Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia 52, 1680-1682 (2009)
54. W.L. Suarez-Pinzon, A. Rabinovitch, Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice. Cell Transplant. 20, 1343-1349 (2011)
55. T.B. Bödvarsdóttir, K.D. Hove, C.F. Gotfredsen, L. Pridal, A. Vaag, A.E. Karlsen, J.S. Petersen, Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia 53, 2220-2223 (2010)
56. L. Bouwens, I. Rooman, Regulation of pancreatic beta-cell mass. Physiol. Rev. 85, 1255-1270 (2005)
57. A.C. Hauge-Evans, A.J. King, D. Carmignac, C.C. Richardson, I.C. Robinson, M.J. Low et al., Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 58, 403-411 (2009)
58. M. Sumii, K. Sumii, A. Tari, M. Yoshihara, K. Haruma, G. Kaji-yama, Regulation of antral peptides by administration of omeprazole to healthy men. Am. J. Gastroenterol. 89, 2033-2037 (1994)
59. S.J. Brand, D. Stone, Reciprocal regulation of antral gastrin and somatostatin gene expression by omeprazole-induced achlorhydria. J. Clin. Invest. 82, 1059-1066 (1988)
60. F. Katagiri, S. Inoue, H. Itoh, M. Takeyama, Omeprazole raises somatostatin and motilin in human plasma. Biol. Pharm. Bull. 28, 370-373 (2005)
61. B. Stoschus, G. Hamscher, S. Ikonomou, G. Partoulas, C. Eberle, T. Sauerbruch et al., Effect of omeprazole treatment on plasma concentrations of the gastric peptides, xenin, gastrin and somatostatin, and of pepsinogen. J. Pept. Res. 52, 27-33 (1998)
62. A. Shulkes, M. Read, Regulation of somatostatin secretion by gastrin- and acid-dependent mechanisms. Endocrinology 129, 2329-2334 (1991)
63. M.A. Read, D.M. Read, M. Kapuscinski, A. Shulkes, Achlorhydria induced changes in gastrin, somatostatin, H+/K(+)-ATPase and carbonic anhydrase in the sheep. Regul. Pept. 40, 13-27 (1992)
64. A. Theodoraki, B. Khoo, A. Hamda, F. Grillo, T. Meyer, P.M. Bou-loux, Malignant somatostatinoma presenting with diabetic ketoacidosis and inhibitory syndrome: pathophysiologic considerations. Endocr. Pract. 16, 835-837 (2010)
65. E. Resmini, F. Minuto, A. Colao, D. Ferone, Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol. 46, 85-95 (2009)
66. G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, A. Giustina, Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94, 1500-1508 (2009)
67. S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Kleinberg et al., Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509-1517 (2009)
68. B.O. Boehm, The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes. Expert Opin. Investig. Drugs 12, 1501-1509 (2003)
69. T. Tzotzas, K. Papazisis, P. Perros, G.E. Krassas, Use of somatostatin analogues in obesity. Drugs 68, 1963-1973 (2008)
70. B.O. Boehm, R.H. Lustig, Use of somatostatin receptor ligands in obesity and diabetic complications. Best Pract. Res. Clin. Gastroenterol. 16, 493-509 (2002)
71. B.E. Dunning, J.E. Gerich, The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr. Rev. 28, 253-283 (2007)
72. L. Yang, S.C. Berk, S.P. Rohrer, R.T. Mosley, L. Guo, D.J. Underwood et al., Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl. Acad. Sci. USA 95, 10836-10841 (1998)
73. K. Cejvan, D.H. Coy, S. Efendic, Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes 52, 1176-1181 (2003)
74. S. Moldovan, A. Atiya, T.E. Adrian, R.M. Kleinman, K. Lloyd, K. Olthoff et al., Somatostatin inhibits B-cell secretion via a subtype-2 somatostatin receptor in the isolated perfused human pancreas. J. Surg. Res. 59, 85-90 (1995)
75. M. Sanaka, T. Yamamoto, Y. Kuyama, Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig. Dis. Sci. 55, 2431-2440 (2010)
76. M.A. Crouch, I.N. Mefford, E.U. Wade, Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. J. Am. Board Fam. Med. 25, 50-54 (2012)
77. B.T. Batuwitage, J.G. Kingham, N.E. Morgan, R.L. Bartlett, Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad. Med. J. 83, 66-68 (2007)
78. M. Eccles, J. Grimshaw, M. Campbell, C. Ramsay, Research designs for studies evaluating the effectiveness of change and improvement strategies. Qual. Saf. Health Care 12, 47-52 (2003)
79. Steno Diabetes Center. The effect of nexium and probiotics on insulin secretion and cardiovascular risk factors in patients with type 2 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00699426NLMIdentifier:NCT00699426 (2000). Accessed 6 June 2012
80. City of Hope Medical Center. Plasm gastrin concentrations in response to nexium administration in healthy volunteers. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/ show/NCT01135472NLMIdentifier:NCT01135472 (2000). Accessed 6 June 2012
81. Sanford Health. Combination therapy with sitagliptin and lansoprazole to restore pancreatic β cell function in recent-onset type 1 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT01155284NLMIdentifier:NCT01155284 (2000). Accessed 6 June 2012
82. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Novel therapy combining regenerative stimuli immunomodulation to preserve β cell function in new onset type 1 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00837759NLMIdentifierNCT00837759 (2000). Accessed 6 June 2012
83. Coordinación de Investigación en Salud, Mexico. Effect of pantoprazole on insulin secretion in patients with type 2 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT01541735NLMIdentifier:NCT01541735 (2000). Accessed 8 June 2012
84. University of Alberta. Pilot study of safety and efficacy of combined use of dipeptidyl-peptidase inhibitor (sitagliptin) and proton pump inhibitor (pantoprazole) to prevent β -cell apoptosis and promote islet regeneration in islet transplant recipients with early graft dysfunction. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). http://clinicaltrials.gov/show/NCT00768651NLMIdentifier:NCT00768651 (2000). Accessed 8 June 2012
85. A.B. Hill, The environment and disease: association or causation? Proc. R. Soc. Med. 58, 295-300 (1965)
86. H.G. Peach, N.E. Barnett, Helicobacter pylori infection and fasting plasma glucose concentration. J. Clin. Pathol. 54, 466-469 (2001)
87. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck et al., Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35, 1364-1379 (2012)
88. D. Boj-Carceller, J. Playán-Usón, P. Trincado-Aznar, F.J. Acha-Pérez, R. Albero-Gamboa. Proton pump inhibitors for the treatment of diabetes mellitus? Av Diabetol 26, 45-46 (2010)